| San Diego Business Journal

Viking’s Stock Climbs Following Competitor’s NASH Results

Viking Therapeutics’ stock has climbed after another company’s disappointing results in the first late-stage clinical trial of a fatty liver disease.

Boutique CROs Find Themselves in Demand

BIOTECH: M&A in the Air at Contract Research Organizations

A crop of San Diego companies quietly play niche roles in drug development. But suitors have taken notice.

Dexcom Reports 53% Increase in Q4 Revenue

Dexcom in fourth quarter financials reported that revenue shot up 53 percent year-over-year to $338 million.

ResMed, Fisher & Paykel Settle Patent Infringement Litigation

A wide-ranging patent dispute between San Diego-based ResMed and Fisher & Paykel Healthcare has come to an end.

NuVasive Reports Q4 Results

NuVasive reported net income of $12.2 million, or $0.23 per share, in fourth quarter results.

Scripps, UC San Diego Health Land Opioid Treatment Grants

Scripps Mercy Hospital San Diego landed a $260,000 grant for opioid disorder treatment, the California Bridge Program recently announced.

Amplyx Pharmaceuticals Snags FDA Orphan Drug Designation

San Diego-based Amplyx Pharmaceuticals’ lead drug candidate received an orphan drug designation for a condition that can be life-threatening for HIV/AIDs patients and others.

AMN Healthcare Reports Fourth Quarter Results

AMN Healthcare recently reported $529 million in fourth quarter revenue, a 4 percent year-over-year increase. San Diego-based AMN is the country’s largest health care staffing agency.

LIfe Sciences: Analysts Skeptical of Smith & Nephew Acquiring NuVasive

A recent report stated that Smith & Nephew Plc has held talks to buy San Diego spine surgery company NuVasive. But analysts largely said the deal doesn’t make sense for the British firm.